B. Riley lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $14 from $17 and keeps a Neutral rating on the shares following the Q1 report. The firm says the company faces significant competition from Padcev -plus pembro in bladder cancer, and a shift toward novel pipeline programs appears unlikely based on current activity.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics price target lowered to $22 from $26 at Citizens JMP
- Bicycle Therapeutics Reports Q1 2025 Progress and Financials
- Bicycle Therapeutics price target lowered to $15 from $40 at Barclays
- Bicycle Therapeutics: Promising Advancements and Strong Financial Position Justify Buy Rating
- Promising Developments in Bicycle Therapeutics’ Pipeline Bolster Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue